A Study of Dementia and Neurological Problems in HIV Infected Patients Who Are Participating in ACTG A5175
International Neurological Study: A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combination for Initial Treatment of HIV-1 Infected Individuals From Diverse Areas of the World)
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Listed as NCT00096824, this observational or N/A phase trial focuses on HIV Infections and remains completed. Sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, it has been updated 8 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jun 2024 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Jun 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Mental Health (NIMH)
For direct contact, visit the study record on ClinicalTrials.gov .